99 related articles for article (PubMed ID: 30754629)
1. Dual Inhibition of DKC1 and MEK1/2 Synergistically Restrains the Growth of Colorectal Cancer Cells.
Kan G; Wang Z; Sheng C; Chen G; Yao C; Mao Y; Chen S
Adv Sci (Weinh); 2021 May; 8(10):2004344. PubMed ID: 34026451
[TBL] [Abstract][Full Text] [Related]
2. IGF1R and Src inhibition induce synergistic cytotoxicity in HNSCC through inhibition of FAK.
Lehman CE; Spencer A; Hall S; Shaw JJP; Wulfkuhle J; Petricoin EF; Bekiranov S; Jameson MJ; Gioeli D
Sci Rep; 2021 May; 11(1):10826. PubMed ID: 34031486
[TBL] [Abstract][Full Text] [Related]
3. The mechanisms of differential sensitivity to an insulin-like growth factor-1 receptor inhibitor (BMS-536924) and rationale for combining with EGFR/HER2 inhibitors.
Huang F; Greer A; Hurlburt W; Han X; Hafezi R; Wittenberg GM; Reeves K; Chen J; Robinson D; Li A; Lee FY; Gottardis MM; Clark E; Helman L; Attar RM; Dongre A; Carboni JM
Cancer Res; 2009 Jan; 69(1):161-70. PubMed ID: 19117999
[TBL] [Abstract][Full Text] [Related]
4. Identification of Lethal Inhibitors and Inhibitor Combinations for Mono-Driver versus Multi-Driver Triple-Negative Breast Cancer Cells.
Ku GC; Chapdelaine AG; Ayrapetov MK; Sun G
Cancers (Basel); 2022 Aug; 14(16):. PubMed ID: 36011019
[TBL] [Abstract][Full Text] [Related]
5. High NRF2 Levels Correlate with Poor Prognosis in Colorectal Cancer Patients and with Sensitivity to the Kinase Inhibitor AT9283 In Vitro.
Torrente L; Maan G; Oumkaltoum Rezig A; Quinn J; Jackson A; Grilli A; Casares L; Zhang Y; Kulesskiy E; Saarela J; Bicciato S; Edwards J; Dinkova-Kostova AT; de la Vega L
Biomolecules; 2020 Sep; 10(10):. PubMed ID: 32992842
[TBL] [Abstract][Full Text] [Related]
6. Advances in dynamic modeling of colorectal cancer signaling-network regions, a path toward targeted therapies.
Tortolina L; Duffy DJ; Maffei M; Castagnino N; Carmody AM; Kolch W; Kholodenko BN; De Ambrosi C; Barla A; Biganzoli EM; Nencioni A; Patrone F; Ballestrero A; Zoppoli G; Verri A; Parodi S
Oncotarget; 2015 Mar; 6(7):5041-58. PubMed ID: 25671297
[TBL] [Abstract][Full Text] [Related]
7. A high-throughput drug combination screen of targeted small molecule inhibitors in cancer cell lines.
Flobak Å; Niederdorfer B; Nakstad VT; Thommesen L; Klinkenberg G; Lægreid A
Sci Data; 2019 Oct; 6(1):237. PubMed ID: 31664030
[TBL] [Abstract][Full Text] [Related]
8. High-throughput RNAi screen for essential genes and drug synergistic combinations in colorectal cancer.
Williams SP; Barthorpe AS; Lightfoot H; Garnett MJ; McDermott U
Sci Data; 2017 Oct; 4():170139. PubMed ID: 28972570
[TBL] [Abstract][Full Text] [Related]
9. Mutational analysis of genes coding for cell surface proteins in colorectal cancer cell lines reveal novel altered pathways, druggable mutations and mutated epitopes for targeted therapy.
Donnard E; Asprino PF; Correa BR; Bettoni F; Koyama FC; Navarro FC; Perez RO; Mariadason J; Sieber OM; Strausberg RL; Simpson AJ; Jardim DL; Reis LF; Parmigiani RB; Galante PA; Camargo AA
Oncotarget; 2014 Oct; 5(19):9199-213. PubMed ID: 25193853
[TBL] [Abstract][Full Text] [Related]
10. Enhancing oncogenic signaling to kill cancer cells.
Noeparast M; Timofeev O; Pichler M
Trends Pharmacol Sci; 2024 Jun; 45(6):475-477. PubMed ID: 38734500
[TBL] [Abstract][Full Text] [Related]
11. Predicting ligand-dependent tumors from multi-dimensional signaling features.
Hass H; Masson K; Wohlgemuth S; Paragas V; Allen JE; Sevecka M; Pace E; Timmer J; Stelling J; MacBeath G; Schoeberl B; Raue A
NPJ Syst Biol Appl; 2017; 3():27. PubMed ID: 28944080
[TBL] [Abstract][Full Text] [Related]
12. Kinase-targeted therapy in subsets of colorectal cancer.
Gomez Barila PM; Medema JP
Oncoscience; 2023; 10():24-26. PubMed ID: 37383222
[No Abstract] [Full Text] [Related]
13. Encorafenib, binimetinib and cetuximab combined therapy for patients with
Huijberts SC; van Geel RM; Bernards R; Beijnen JH; Steeghs N
Future Oncol; 2020 Feb; 16(6):161-173. PubMed ID: 32027186
[TBL] [Abstract][Full Text] [Related]
14. Challenges and Opportunities in Developing Targeted Therapies for Triple Negative Breast Cancer.
Chapdelaine AG; Sun G
Biomolecules; 2023 Aug; 13(8):. PubMed ID: 37627272
[TBL] [Abstract][Full Text] [Related]
15. Dasatinib in combination with BMS-754807 induce synergistic cytotoxicity in lung cancer cells through inhibiting lung cancer cell growth, and inducing autophagy as well as cell cycle arrest at the G1 phase.
Zhang C; Zhao X; Wang Z; Gong T; Zhao H; Zhang D; Niu Y; Li X; Zhao X; Li G; Dong X; Zhang L; Liu C; Xu J; Yu B
Invest New Drugs; 2023 Jun; 41(3):438-452. PubMed ID: 37097369
[TBL] [Abstract][Full Text] [Related]
16. Application of a Biphasic Mathematical Model of Cancer Cell Drug Response for Formulating Potent and Synergistic Targeted Drug Combinations to Triple Negative Breast Cancer Cells.
Shen J; Li L; Howlett NG; Cohen PS; Sun G
Cancers (Basel); 2020 Apr; 12(5):. PubMed ID: 32349331
[TBL] [Abstract][Full Text] [Related]
17. Biphasic Mathematical Model of Cell-Drug Interaction That Separates Target-Specific and Off-Target Inhibition and Suggests Potent Targeted Drug Combinations for Multi-Driver Colorectal Cancer Cells.
Shen J; Li L; Yang T; Cohen PS; Sun G
Cancers (Basel); 2020 Feb; 12(2):. PubMed ID: 32069833
[TBL] [Abstract][Full Text] [Related]
18. Drug Sensitivity Screening and Targeted Pathway Analysis Reveal a Multi-Driver Proliferative Mechanism and Suggest a Strategy of Combination Targeted Therapy for Colorectal Cancer Cells.
Shen J; Li L; Yang T; Cheng N; Sun G
Molecules; 2019 Feb; 24(3):. PubMed ID: 30754629
[TBL] [Abstract][Full Text] [Related]
19. Combined Inhibition of IGF-1R/IR and Src family kinases enhances antitumor effects in prostate cancer by decreasing activated survival pathways.
Dayyani F; Parikh NU; Varkaris AS; Song JH; Moorthy S; Chatterji T; Maity SN; Wolfe AR; Carboni JM; Gottardis MM; Logothetis CJ; Gallick GE
PLoS One; 2012; 7(12):e51189. PubMed ID: 23300537
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
